Abstract # 2321 A Phase II Trial of Varian Trilogy-based SBRT for Low-Risk Prostate Cancer: Report of Early Toxicity and Disease Control Outcomes

Presenter: Constantine Mantz


Abstract:


E-mail a friend about this poster:
Enter email address: